News | June 07, 2022
MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
To address the preventive & primary healthcare delivery gaps in India
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
Successfully removed peanut from the child’s left lung through bronchoscopy
Subscribe To Our Newsletter & Stay Updated
